New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - ivacaftor 125mg;  ; lumacaftor 100mg;   - film coated tablet - active: ivacaftor 125mg   lumacaftor 100mg   excipient: croscarmellose sodium hypromellose acetate succinate magnesium stearate microcrystalline cellulose opacode black s-1-17823 opadry pink 85f140026 povidone sodium laurilsulfate water - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 2 years and older who are homozygous for the f508del mutation in the cftr gene.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - ivacaftor 125mg;  ; lumacaftor 200mg;   - film coated tablet - active: ivacaftor 125mg   lumacaftor 200mg   excipient: croscarmellose sodium hypromellose acetate succinate magnesium stearate microcrystalline cellulose opacode black s-1-17823 opadry pink 85f140026 povidone sodium laurilsulfate water - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 2 years and older who are homozygous for the f508del mutation in the cftr gene.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - ivacaftor 125mg;  ; lumacaftor 100mg;   - oral granules - active: ivacaftor 125mg   lumacaftor 100mg   excipient: croscarmellose sodium hypromellose acetate succinate microcrystalline cellulose povidone sodium laurilsulfate - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 2 years and older who are homozygous for the f508del mutation in the cftr gene.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - ivacaftor 188mg;  ; lumacaftor 150mg;   - oral granules - active: ivacaftor 188mg   lumacaftor 150mg   excipient: croscarmellose sodium hypromellose acetate succinate microcrystalline cellulose povidone sodium laurilsulfate - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 2 years and older who are homozygous for the f508del mutation in the cftr gene.

Australia - English - Department of Health (Therapeutic Goods Administration)

vertex pharmaceuticals australia pty ltd - ivacaftor, quantity: 125 mg; lumacaftor, quantity: 100 mg - tablet, film coated - excipient ingredients: hypromellose acetate succinate; sodium lauryl sulfate; microcrystalline cellulose; povidone; magnesium stearate; croscarmellose sodium; titanium dioxide; purified water; purified talc; brilliant blue fcf aluminium lake; polyvinyl alcohol; macrogol 3350; cochineal; indigo carmine aluminium lake; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

pharmacare premium limited - capecitabine - tablets film-coated - 500mg

Malta - English - Medicines Authority

pharmacare srl via marghera, 29 20149, milan, italy - tablet - vildagliptin 50 mg - drugs used in diabetes

Malta - English - Medicines Authority

pharmacare premium limited hhf 003 halfar industrial estate birzebbugia bbg 3000, malta - film-coated tablet - capecitabine 150 mg - antineoplastic agents

Malta - English - Medicines Authority

pharmacare premium limited hhf 003 halfar industrial estate birzebbugia bbg 3000, malta - film-coated tablet - capecitabine 500 mg - antineoplastic agents

Malta - English - Medicines Authority

pharmacare premium limited hhf 003 halfar industrial estate birzebbugia bbg 3000, malta - film-coated tablet - pazopanib 200 mg - antineoplastic agents